Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cerebrospinal fluid biomarkers of neurodegeneration are decreased or normal in narcolepsy

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{974a94f8281144728396a6ccc086869c,
title = "Cerebrospinal fluid biomarkers of neurodegeneration are decreased or normal in narcolepsy",
abstract = "OBJECTIVES: To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration.METHODS: Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases) aged 33 years on average, and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1).RESULTS: Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ±143.5 pg/ml) and type 2 narcolepsy (455.9 ± 65.0 pg/ml) compared with controls (697.9 ± 167.3 pg/ml, p < 0.05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/ml), and P-tau181 (19.1 ± 4.3 pg/ml) were lower than in controls (162.2 ± 49.9 pg/ml and 33.8 ± 9.2 pg/ml, p < 0.05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals.CONCLUSION: Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in CNS.",
author = "Jennum, {Poul J{\o}rgen} and Pedersen, {Lars {\O}stergaard} and Bahl, {Justyna Maria Czarna} and Stausb{\o}ll, {Signe Modvig} and Karina Fog and Anja Holm and Kornum, {Birgitte Rahbek} and Steen Gammeltoft",
note = "Copyright {\circledC} 2017 Sleep Research Society All rights reserved.",
year = "2017",
month = "1",
language = "English",
volume = "40",
pages = "zsw006",
journal = "Sleep",
issn = "0161-8105",
publisher = "The/American Academy of Sleep Medicine",
number = "1",

}

RIS

TY - JOUR

T1 - Cerebrospinal fluid biomarkers of neurodegeneration are decreased or normal in narcolepsy

AU - Jennum, Poul Jørgen

AU - Pedersen, Lars Østergaard

AU - Bahl, Justyna Maria Czarna

AU - Stausbøll, Signe Modvig

AU - Fog, Karina

AU - Holm, Anja

AU - Kornum, Birgitte Rahbek

AU - Gammeltoft, Steen

N1 - Copyright © 2017 Sleep Research Society All rights reserved.

PY - 2017/1

Y1 - 2017/1

N2 - OBJECTIVES: To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration.METHODS: Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases) aged 33 years on average, and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1).RESULTS: Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ±143.5 pg/ml) and type 2 narcolepsy (455.9 ± 65.0 pg/ml) compared with controls (697.9 ± 167.3 pg/ml, p < 0.05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/ml), and P-tau181 (19.1 ± 4.3 pg/ml) were lower than in controls (162.2 ± 49.9 pg/ml and 33.8 ± 9.2 pg/ml, p < 0.05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals.CONCLUSION: Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in CNS.

AB - OBJECTIVES: To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration.METHODS: Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases) aged 33 years on average, and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1).RESULTS: Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ±143.5 pg/ml) and type 2 narcolepsy (455.9 ± 65.0 pg/ml) compared with controls (697.9 ± 167.3 pg/ml, p < 0.05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/ml), and P-tau181 (19.1 ± 4.3 pg/ml) were lower than in controls (162.2 ± 49.9 pg/ml and 33.8 ± 9.2 pg/ml, p < 0.05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals.CONCLUSION: Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in CNS.

M3 - Journal article

VL - 40

SP - zsw006

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 1

ER -

ID: 49464512